Russell Investments Group Ltd. raised its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 80.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,269,283 shares of the medical equipment provider’s stock after purchasing an additional 1,011,363 shares during the quarter. Russell Investments Group Ltd. owned 2.58% of Accuray worth $8,783,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Swiss National Bank lifted its holdings in shares of Accuray by 3.6% in the second quarter. Swiss National Bank now owns 163,600 shares of the medical equipment provider’s stock valued at $633,000 after purchasing an additional 5,700 shares in the last quarter. Bailard Inc. grew its holdings in Accuray by 28.6% during the second quarter. Bailard Inc. now owns 27,400 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 6,100 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Accuray by 18.5% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 53,054 shares of the medical equipment provider’s stock valued at $205,000 after buying an additional 8,300 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Accuray in the 1st quarter valued at $49,000. Finally, Quantitative Systematic Strategies LLC lifted its stake in Accuray by 92.2% during the 2nd quarter. Quantitative Systematic Strategies LLC now owns 28,367 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 13,605 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.
NASDAQ:ARAY traded up $0.12 on Wednesday, hitting $3.13. The stock had a trading volume of 7,578 shares, compared to its average volume of 726,229. The company has a debt-to-equity ratio of 3.21, a quick ratio of 1.16 and a current ratio of 1.79. The stock has a market cap of $275.22 million, a P/E ratio of -20.69 and a beta of 1.96. Accuray Incorporated has a 1 year low of $2.35 and a 1 year high of $5.40. The firm’s fifty day simple moving average is $3.24 and its two-hundred day simple moving average is $3.96.
Accuray (NASDAQ:ARAY) last posted its earnings results on Thursday, August 15th. The medical equipment provider reported ($0.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.05). The firm had revenue of $117.42 million for the quarter, compared to the consensus estimate of $116.09 million. Accuray had a negative return on equity of 26.69% and a negative net margin of 3.92%. During the same period in the prior year, the business earned ($0.01) EPS. Equities research analysts predict that Accuray Incorporated will post -0.14 EPS for the current year.
A number of equities analysts have issued reports on the stock. BidaskClub raised shares of Accuray from a “strong sell” rating to a “sell” rating in a report on Tuesday. Royal Bank of Canada set a $4.00 target price on shares of Accuray and gave the company a “hold” rating in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $4.47.
In related news, CEO Joshua Levine sold 56,426 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $3.75, for a total transaction of $211,597.50. Following the completion of the sale, the chief executive officer now owns 977,167 shares in the company, valued at $3,664,376.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew J. Kirkpatrick sold 8,222 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $3.75, for a total transaction of $30,832.50. Following the sale, the insider now owns 232,414 shares of the company’s stock, valued at approximately $871,552.50. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Recommended Story: What does it mean to hold a stock in street name?
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.